Literature DB >> 22247788

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

Alexis Mollard1, Steven L Warner, Lee T Call, Mark L Wade, Jared J Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati, David J Bearss.   

Abstract

The receptor tyrosine kinase AXL has emerged in recent years as an potential oncology target due to its over expression in several types of cancers coupled with its ability to promote tumor growth and metastasis. In order to identify small molecule inhibitors of AXL, we built a homology model of its catalytic domain to virtually screen and identify scaffolds displaying an affinity for AXL. Further computational and structure-based design resulted in the synthesis of a series of 2,4,5-trisubstitued pyrimidines which demonstrated potent inhibition of AXL in vitro (IC(50) 19 nM) and strongly inhibited the growth of several pancreatic cell lines.

Entities:  

Year:  2011        PMID: 22247788      PMCID: PMC3254106          DOI: 10.1021/ml200198x

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  11 in total

1.  Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway.

Authors:  Tateo Sawabu; Hiroshi Seno; Tomoko Kawashima; Akihisa Fukuda; Yoshito Uenoyama; Mayumi Kawada; Naoki Kanda; Akira Sekikawa; Hirokazu Fukui; Motoko Yanagita; Hiroshi Yoshibayashi; Seiji Satoh; Yoshiharu Sakai; Toru Nakano; Tsutomu Chiba
Journal:  Mol Carcinog       Date:  2007-02       Impact factor: 4.784

2.  R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

Authors:  Sacha J Holland; Alison Pan; Christian Franci; Yuanming Hu; Betty Chang; Weiqun Li; Matt Duan; Allan Torneros; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Ayodele Apatira; Joanne Chua; Ralf Brandt; Polly Pine; Dane Goff; Rajinder Singh; Donald G Payan; Yasumichi Hitoshi
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

3.  Gas6 anti-apoptotic signaling requires NF-kappa B activation.

Authors:  F Demarchi; R Verardo; B Varnum; C Brancolini; C Schneider
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

4.  An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.

Authors:  X Ye; Y Li; S Stawicki; S Couto; J Eastham-Anderson; D Kallop; R Weimer; Y Wu; L Pei
Journal:  Oncogene       Date:  2010-07-05       Impact factor: 9.867

Review 5.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

6.  A putative receptor tyrosine kinase with unique structural topology.

Authors:  J Rescigno; A Mansukhani; C Basilico
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

7.  Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase.

Authors:  Y W Fridell; Y Jin; L A Quilliam; A Burchert; P McCloskey; G Spizz; B Varnum; C Der; E T Liu
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

8.  Transforming genes in chronic myelogenous leukemia.

Authors:  E Liu; B Hjelle; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.

Authors:  Y Li; X Ye; C Tan; J-A Hongo; J Zha; J Liu; D Kallop; M J C Ludlam; L Pei
Journal:  Oncogene       Date:  2009-07-27       Impact factor: 9.867

10.  The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.

Authors:  T N Stitt; G Conn; M Gore; C Lai; J Bruno; C Radziejewski; K Mattsson; J Fisher; D R Gies; P F Jones
Journal:  Cell       Date:  1995-02-24       Impact factor: 41.582

View more
  25 in total

1.  Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease.

Authors:  Miles A Miller; Eunha Kim; Michael F Cuccarese; Alec L Plotkin; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Chem Commun (Camb)       Date:  2017-12-19       Impact factor: 6.222

Review 2.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

3.  Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.

Authors:  Kartik W Temburnikar; Sarah C Zimmermann; Nathaniel T Kim; Christina R Ross; Christopher Gelbmann; Christine E Salomon; Gerald M Wilson; Jan Balzarini; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem       Date:  2014-03-03       Impact factor: 3.641

4.  Imaging Axl expression in pancreatic and prostate cancer xenografts.

Authors:  Sridhar Nimmagadda; Mrudula Pullambhatla; Ala Lisok; Chaoxin Hu; Anirban Maitra; Martin G Pomper
Journal:  Biochem Biophys Res Commun       Date:  2013-12-11       Impact factor: 3.575

5.  The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.

Authors:  Ketan S Gajiwala; Neil Grodsky; Ben Bolaños; Junli Feng; RoseAnn Ferre; Sergei Timofeevski; Meirong Xu; Brion W Murray; Ted W Johnson; Al Stewart
Journal:  J Biol Chem       Date:  2017-07-19       Impact factor: 5.157

6.  Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

Authors:  Bálint Szokol; Pál Gyulavári; Ibolya Kurkó; Ferenc Baska; Csaba Szántai-Kis; Zoltán Greff; Zoltán Orfi; István Peták; Kinga Pénzes; Robert Torka; Axel Ullrich; László Orfi; Tibor Vántus; György Kéri
Journal:  ACS Med Chem Lett       Date:  2014-01-30       Impact factor: 4.345

7.  Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Authors:  Sutapa Sinha; Justin Boysen; Michael Nelson; Charla Secreto; Steven L Warner; David J Bearss; Connie Lesnick; Tait D Shanafelt; Neil E Kay; Asish K Ghosh
Journal:  Clin Cancer Res       Date:  2015-02-11       Impact factor: 12.531

Review 8.  Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis.

Authors:  Tian Zhu; Shuyi Cao; Pin-Chih Su; Ram Patel; Darshan Shah; Heta B Chokshi; Richard Szukala; Michael E Johnson; Kirk E Hevener
Journal:  J Med Chem       Date:  2013-06-07       Impact factor: 7.446

9.  Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer.

Authors:  Lidia Bosurgi; Jochem H Bernink; Victor Delgado Cuevas; Nicola Gagliani; Leonel Joannas; Edward T Schmid; Carmen J Booth; Sourav Ghosh; Carla V Rothlin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

10.  A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Authors:  K E Ware; T K Hinz; E Kleczko; K R Singleton; L A Marek; B A Helfrich; C T Cummings; D K Graham; D Astling; A-C Tan; L E Heasley
Journal:  Oncogenesis       Date:  2013-03-25       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.